Q2 results on Oct 26, 2016
Cadila Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on October 26, 2016, inter alia, to consider to approve the unaudited financial results for the quarter / half year ended on September 30, 2016 (Q2).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain... Zydus signs in-licensing deal with Neovii of Switzerland
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated October 06, 2016 titled "Zydus signs in-licensing deal with Neovii of Switzerland". Zydus and Medicines for Malaria Venture Sign Agreement to Develop Potential New Antimalarial Drug
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated September 30, 2016 titled "Zydus and Medicines for Malaria Venture Sign Agreement to Develop Potential New Antimalarial Drug". Zydus Cadila ties up with Takeda to develop chikungunya vaccine
Drug firm Zydus Cadila today announced partnership with Japan's Takeda Pharmaceutical Company Ltd to develop a vaccine for chikungunya. The broad-based agreement includes early stage development to Zydus and Takeda enter into partnership to address emerging infectious diseases
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated September 20, 2016 titled "Zydus and Takeda enter into partnership to address emerging infectious diseases" Cadila Healthcare gains on EIR for Ahmedabad facility
The stock moved higher by 4% to Rs 391 on the BSE. Updates
Cadila Healthcare Ltd has informed BSE that the Company's Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility. Now, Roche takes Zydus Cadila to court over breast cancer drug
The petition states the approval of Cadila's drug as a biosimilar has caused Roche irreparable damage in violation of applicable law for testing and approval of biosimilar drugs.
Cadila gets EIR from USFDA for Changodar topical facility
Receipt of the EIR indicates that the USFDA has closed the inspection, as the company has addressed observations related to good manufacturing practices raised Updates
Cadila Healthcare Ltd has informed BSE that the Company's Topical manufacturing facility located at Changodar, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in March 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant.